NINLARO® (Ixazomib) – der erste orale Proteasom-Inhibitor neu bei Multiplem Myelom in der Schweiz zugelassen Share: Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me Forgot password? Click here
Do you want to read an article? Please log in or register. E mail Password Login Register for Free Remember me
